First Partnership for CollabRx with Private Oncology Company; Expands Presence in Asia
SAN FRANCISCO —June26, 2014– CollabRx, Inc. (NASDAQ: CLRX), a data analytics company and leading provider of expert systems that inform therapeutic decision-making in oncology, and OncoSolutions Cancer Center, a private oncology company based in Singapore, announce a multiyear agreement. CollabRx will provide its Genetic Variant Annotation (GVA) Service™ to oncologists at OncoSolutions so they can quickly and efficiently glean insight from a patient’s tumor genetic profile to determine a treatment plan. This “precision medicine” approach to treatment planning is key to evaluating all possible therapy options to provide the best possible patient care and optimize clinical outcomes.
The GVA service pairs tumor genetic alterations derived from established next-generation sequencing (NGS) platforms with concise textual narratives that describe drugs and clinical trials. It utilizes scientific data and other information, including clinical treatment guidelines, peer-reviewed publications, case reports and other sources of knowledge to develop actionable information for oncologists.
“A contextualized and easy-to-understand interpretation of NGS-based tests is required to make the results of such tests useful for clinical oncologists,” said Dr. Terence Aik Huang Tan, Founder and Chief Oncologist at OncoSolutions. “CollabRx has developed a comprehensive collection of dynamically updated precision oncology treatment strategies that are developed in collaboration with leading physicians and are optimized for use by physicians. These concise, readily understood narratives efficiently summarize the body of knowledge in molecular oncology and provide cancer type-specific therapy options for consideration. We are enthusiastic about leveraging CollabRx’s expertise so we can provide the highest-quality care to cancer patients.”
“This partnership with OncoSolutions represents CollabRx’s first such commercial relationship with a private oncology company and we are proud to be associated with this prominent group of physicians,” said Thomas Mika, Chairman, President & CEO of CollabRx. “This new milestone for CollabRx attests to the growing adoption of our technology and interpretive analytics as a standard aspect of test reporting for clinical genetic sequencing in cancer, and further expands the company’s presence in Asia.”
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
About OncoSolutions Cancer Center
OncoSolutions is a private oncology practice based at Mount Elizabeth Novena Specialist Center in Singapore. OncoSolutions was founded by Dr. Terence Aik Huang Tan, a leading medical oncologist in Singapore with expertise in molecular medicine and medical informatics. Dr. Tan obtained his medical training in Ireland, the U.K., and the U.S. before returning to Singapore to establish OncoSolutions. Dr. Tan leads a team of physicians, translational scientists, bioinformaticians, and clinical trial specialists to develop “precision oncology” based treatment plans to inform the care of cancer patients in Singapore and throughout Asia. More information may be obtained at http://www.oncosolutions.com.sg.
This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Gavin J. Gordon, MBA, PhD
Vice President of Business Development & Strategic Alliances
Dian Griesel Int’l.
OncoSolutions Cancer CenterContact:
Terence Aik Huang Tan, MD, MSc
OncoSolutions Cancer Center